Adiponectin
Also known as: ACRP30, AdipoQ, GBP-28, apM1, adipocyte complement-related protein, adipocyte complement-related protein of 30 kDa, gelatin-binding protein 28, AdipoRon receptor agonist target, ADIPOQ protein, ADIPOQ gene product
Endogenous adipokine — adipocyte-secreted peptide hormone; 30-kDa collagen-domain-containing pleiotropic metabolic and anti-inflammatory regulator
What it is
People managing weight, blood sugar, or heart health may hear about adiponectin — a hormone naturally released by fat cells that actually fights the harmful effects of excess body fat. Low adiponectin levels are consistently linked to insulin resistance, type 2 diabetes, and fatty liver disease, making it a key target for metabolic therapies and lifestyle interventions.
The scientific side
adiponectin is a 30-kDa adipokine synthesized and secreted predominantly by differentiated adipocytes, encoded by the ADIPOQ gene on chromosome 3q27. Unlike most adipokines, adiponectin circulates at relatively high plasma concentrations (5–30 µg/mL in healthy individuals) and its levels are paradoxically reduced in states of adipose tissue expansion — including obesity, type 2 diabetes mellitus, and metabolic syndrome — while being elevated in lean and physically active individuals. Adiponectin exists in three oligomeric forms in plasma: trimers (low-molecular-weight), hexamers (medium-molecular-weight), and high-molecular-weight (HMW) multimers composed of 12–18 subunits; the HMW form is considered the most biologically active in terms of insulin-sensitizing effects. Adiponectin signals primarily through two transmembrane receptors: AdipoR1, expressed widely in skeletal muscle, and AdipoR2, expressed predominantly in the liver. Both receptors are seven-transmembrane proteins with structural similarity to G-protein-coupled receptors but with an inverted topology and intrinsic ceramidase activity. Ligand binding to AdipoR1 and AdipoR2 activates AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-alpha (PPARα) signaling cascades. AMPK activation increases fatty acid oxidation in skeletal muscle and liver, suppresses hepatic glucose production, and improves insulin signaling by reducing cellular lipotoxic intermediates such as ceramide and diacylglycerol. PPARα activation in the liver promotes mitochondrial beta-oxidation and reduces hepatic steatosis. In the vasculature, adiponectin activates endothelial nitric oxide synthase (eNOS), increasing nitric oxide bioavailability, reducing oxidative stress, inhibiting nuclear factor-kappa B (NF-κB)-mediated inflammatory gene expression, and suppressing adhesion molecule expression (VCAM-1, ICAM-1, E-selectin), collectively reducing endothelial dysfunction and atherosclerotic plaque formation. In macrophages, adiponectin promotes M2 anti-inflammatory polarization, suppresses TNF-α and IL-6 secretion, and reduces foam cell formation. In the liver, adiponectin suppresses hepatic stellate cell activation, thereby attenuating fibrosis in non-alcoholic fatty liver disease (NAFLD/MASLD). ADIPOQ gene polymorphisms, including rs2241767 and other single-nucleotide variants, influence circulating adiponectin concentrations and have been linked to individual risk for type 2 diabetes and cardiovascular disease in genetic epidemiology studies. Exercise, caloric restriction, certain pharmacological agents (thiazolidinediones, SGLT2 inhibitors), and Mediterranean dietary patterns are among the best-documented interventions that raise endogenous adiponectin levels.
Class: Endogenous adipokine — adipocyte-secreted peptide hormone; 30-kDa collagen-domain-containing pleiotropic metabolic and anti-inflammatory regulator
Administration & storage
- Administration
- Intravenous infusion — used in some animal models for pharmacokinetic studiesIntraperitoneal injection — common route in rodent preclinical studiesSubcutaneous injection — explored in preclinical models; not established in humansOral administration (AdipoRon small-molecule agonist only) — the preferred route in preclinical receptor agonist studies given its oral bioavailability in rodents
- Storage
- Research-grade recombinant adiponectin (laboratory use only): store lyophilized powder at -20°C or -80°C per manufacturer instructions. Reconstituted solutions should be aliquoted and stored at -80°C to avoid freeze-thaw degradation of the HMW oligomeric forms. Avoid repeated freeze-thaw cycles, which disrupt complex multimer assembly. Not applicable to any human therapeutic context as no approved product exists.
- Cautions
- No approved human therapeutic adiponectin product exists — self-administration of any adiponectin preparation carries unknown and unquantified risks,Research-grade recombinant adiponectin products are not manufactured to pharmaceutical-grade purity and may contain endotoxin, host cell protein contaminants, or preservatives unsuitable for human injection,Adiponectin has potent insulin-sensitizing effects — theoretical risk of hypoglycemia if administered exogenously in combination with insulin or insulin secretagogues,The complex oligomeric structure of adiponectin means that improperly folded or truncated recombinant preparations may have different biological activity profiles and unpredictable receptor-binding kinetics,AdipoRon and related synthetic receptor agonists have not undergone human safety evaluation — all safety data are from rodent models only,Individuals with pre-existing hypotension, advanced liver disease, or severe metabolic syndrome should not attempt any experimental peptide administration without medical supervision
Legal & regulatory status
Adiponectin (recombinant or native) has no FDA-approved therapeutic indication in the United States. No recombinant adiponectin product has received FDA approval for any disease. Adiponectin circulating levels are…
Adiponectin is not listed as a prohibited substance on the current WADA Prohibited List. As an endogenous hormone naturally produced by adipose tissue, adiponectin itself would not be classified as prohibited under…
No Health Canada Drug Identification Number (DIN) exists for any therapeutic adiponectin product. Recombinant adiponectin has not been approved as a drug or biologic by Health Canada. Plasma adiponectin measurement may…
What it's studied for
- Insulin resistance and type 2 diabetes — adiponectin as biomarker and therapeutic target Established Biomarker / Multiple Epidemiological and Genetic Studies
- Non-alcoholic fatty liver disease (NAFLD/MASLD) — hepatoprotective and anti-fibrotic role Case-Control Study / Biomarker Association
- Cardiovascular disease and atherosclerosis — cardioprotective and anti-atherosclerotic biomarker Observational / Cross-Sectional Cohort
- Exercise-induced metabolic benefit — adiponectin as mediator of training adaptations Randomized Controlled Trial (Secondary Outcomes)
- Mental health and depression comorbidity in chronic heart failure — AdipoRon receptor agonism Clinical Observational + Preclinical Animal Model
- Rheumatoid arthritis and autoimmune joint disease — AdipoRon as anti-inflammatory therapeutic (preclinical) Preclinical Animal Model + In Vitro
- Renal disease — AdipoRon renoprotection in preclinical kidney injury models Systematic Review and Meta-Analysis of Preclinical Studies
- Diet and fasting interventions — adiponectin as metabolic response biomarker Non-Randomized Controlled Trial
Safety signals
- Theoretical hypoglycemia risk with exogenous administration in insulin-treated patients
- Hypoadiponectinemia as a pathological risk marker — very low levels associated with heightened cardiometabolic risk, not a safety signal of exogenous use
- Lack of pharmaceutical-grade manufacturing — research-grade recombinant adiponectin may contain endotoxin or contaminants; risk of pyrogenic or immune reaction if injected
- ADIPOQ gene polymorphisms affect circulating levels and disease risk — pharmacogenomic consideration for any future therapeutic application
- AdipoRon (receptor agonist) — hepatotoxicity and weight effects observed at high doses in some rodent studies; safety profile in humans entirely unknown
- Paradoxical elevation of adiponectin in end-stage renal disease and heart failure — context-dependent biology that complicates interpretation
- No known long-term safety data for any exogenous adiponectin administration in humans — absence of safety data is itself a signal requiring caution
No peer-reviewed studies indexed for this peptide yet.
Frequently asked
Can I inject adiponectin to lose weight or improve my blood sugar?
There is no approved injectable adiponectin product for human use anywhere in the world. Research-grade recombinant adiponectin sold by laboratory suppliers is explicitly not manufactured for human injection — it may contain contaminants, pyrogens, or impurities that could cause serious harm. The best-evidenced ways to raise your own adiponectin levels are regular exercise (especially high-intensity interval training or resistance training), caloric restriction or intermittent fasting, and if medically indicated, certain prescription diabetes medications such as pioglitazone under a physician's supervision.
What does it mean if my adiponectin levels are low?
Low circulating adiponectin (typically below 5 µg/mL) is consistently associated with insulin resistance, type 2 diabetes, excess visceral fat, fatty liver disease, and higher cardiovascular risk. It reflects reduced protective signaling from adipose tissue and is often seen alongside high BMI, low physical activity, and poor dietary quality. Low adiponectin is an indicator of metabolic risk — not a diagnosis in itself — and should be interpreted by your physician alongside other metabolic markers, your clinical history, and lifestyle factors.
What is AdipoRon and is it available for humans?
AdipoRon is a synthetic small-molecule compound that activates adiponectin receptors (AdipoR1 and AdipoR2) in a similar way to the natural hormone. It has shown promising results in animal models for conditions including diabetes, kidney disease, rheumatoid arthritis, and depression comorbid with heart failure. As of 2026, AdipoRon has not been tested in human clinical trials and is not approved or available as a pharmaceutical for human use. It is sold by chemical suppliers for laboratory research purposes only and should not be self-administered.
Does exercise really raise adiponectin levels?
Yes — regular exercise, especially high-intensity interval training (HIIT) and resistance training, consistently raises circulating adiponectin levels. Clinical studies show that 12-week exercise programs can increase adiponectin significantly in obese adolescents, older adults, and people with metabolic syndrome, alongside improvements in insulin sensitivity and inflammation markers. The adiponectin increase appears to reflect improved adipose tissue function as excess fat is reduced and muscle mass is built. Both aerobic and strength-based programmes produce benefit, with greater effect sizes typically seen in people who start with low adiponectin and higher baseline adiposity.
Is adiponectin related to GLP-1 drugs like semaglutide or Ozempic?
They work through different mechanisms but overlap in metabolic effects. GLP-1 receptor agonists like semaglutide reduce body weight and improve insulin sensitivity, and biomarker sub-studies have shown that they also raise adiponectin levels as a secondary effect — possibly through weight loss-driven adipose tissue remodeling. Adiponectin is not the primary target of GLP-1 drugs, but rising adiponectin may contribute to some of their anti-inflammatory and cardiovascular protective effects. Neither drug type is a substitute for the other, and none are equivalent to exogenous adiponectin supplementation.